Wells Fargo’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-13,462
| Closed | -$644K | – | 7354 |
|
|
2025
Q3 | $644K | Buy |
13,462
+1,248
| +10% | +$34.6K | ﹤0.01% | 4115 |
|
|
2025
Q2 | $195K | Sell |
12,214
-1,640
| -12% | -$26.6K | ﹤0.01% | 4790 |
|
|
2025
Q1 | $211K | Buy |
13,854
+305
| +2% | +$4.89K | ﹤0.01% | 4669 |
|
|
2024
Q4 | $275K | Buy |
13,549
+2,951
| +28% | +$74.3K | ﹤0.01% | 4591 |
|
|
2024
Q3 | $272K | Buy |
10,598
+455
| +4% | +$7.59K | ﹤0.01% | 4378 |
|
|
2024
Q2 | $130K | Buy |
10,143
+10,017
| +7,950% | +$161K | ﹤0.01% | 4783 |
|
|
2024
Q1 | $2.88K | Buy |
126
+43
| +52% | +$1.52K | ﹤0.01% | 5978 |
|
|
2023
Q4 | $2.17K | Buy |
83
+69
| +493% | +$1.38K | ﹤0.01% | 6095 |
|
|
2023
Q3 | $391 | Sell |
14
-2
| -13% | -$59 | ﹤0.01% | 6414 |
|
|
2023
Q2 | $471 | Sell |
16
-393
| -96% | -$10K | ﹤0.01% | 6501 |
|
|
2023
Q1 | $7.69K | Buy |
+409
| New | +$6.75K | ﹤0.01% | 5936 |
|
|
2022
Q4 | – | Sell |
-5
| Closed | – | – | 7734 |
|
|
2022
Q3 | $0 | Sell |
5
-15
| -75% | -$546 | ﹤0.01% | 7383 |
|
|
2022
Q2 | $1K | Sell |
20
-54
| -73% | -$4.26K | ﹤0.01% | 6614 |
|
|
2022
Q1 | $7K | Sell |
74
-790
| -91% | -$73.9K | ﹤0.01% | 6398 |
|
|
2021
Q4 | $132K | Buy |
+864
| New | +$128K | ﹤0.01% | 5492 |
|
Wells Fargo's TRML Position: Q4 2025 in Review
Wells Fargo sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 13,462 shares — an estimated $644K sold.
Wells Fargo first reported a position in TRML in Q4 2021 and held it in 15 quarters. The position peaked at $644K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Wells Fargo reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Wells Fargo sold 13,462 Tourmaline Bio shares in Q4 2025, an estimated $644K.
- Wells Fargo first reported a position in Tourmaline Bio in Q4 2021 and held it in 15 quarters.
- Wells Fargo's Tourmaline Bio position peaked at $644K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Wells Fargo's 13F filing for Q4 2025, filed 13 Feb 2026.